

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Competitive Grant Program Eligibility

Geographic Scope	Global (excluding U.S.*) *The Inflammatory and Immune-Mediated Dermatologic Disorders Competitive Grant Program for the U.S. can be found here.
Applicant Eligibility Criteria	 To be eligible: The institution and principal investigator (PI) must be based in one of the eligible countries noted above. Only organizations are eligible to receive grants, not individuals or medical practice groups. The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. Applicant must be affiliated with a host institution

Requirements

Date RFP Issued	December 16, 2020
Clinical Area	Inflammatory and Immune-mediated Dermatologic Disorders
Area of Interest Focus	The intent of this Request for Proposal (RFP) is to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders. For all areas, there is a particular interest in supporting research on treatment response in in all Fitzpatrick skin types. For atopic dermatitis, there is complementary interest in low disease activity monitoring. Areas of Research Focus
	 JAK/STATi effects on itch and/or sleep in patients with atopic dermatitis JAK/STATi effects on barrier dysfunction in patients with atopic dermatitis Research and new insights into the burden and/or epidemiology of alopecia areata





	Out of Scope
	 Research proposals that conflict with ongoing Pfizer-sponsored trials or future development plans are out of scope.
	 Research proposals that require drug supply for investigational JAK- inhibitors
Expected Approximate Monetary Range of Grant Applications	 Individual projects requesting up to \$150,000 will be considered. Pfizer anticipates awarding up to 8 grants
	The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel's evaluation of the proposal and costs involved, and will be stated clearly in the approval notification
Key Dates	RFP release date: December 16, 2020
	Full Proposal due date: March 10, 2021
	Please note the deadline is midnight Eastern Standard Time (e.g. New York, GMT -5).
	 Review of Full Proposals by ERP: April 2021
	Anticipated Full Proposal Notification Date: June 2021
How to Apply	Please go to www.cybergrants.com/pfizer/Research and sign in. First-
	time users should click "Create your password".
	Requirements for submission:
	 Select the following Competitive Grant Program Name: 2020 I&I G Inflammatory and Immune-Mediated Dermatologic Disorders (Global)
	 Complete all required sections of the online application. See Appendix A for additional details
	 If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page





Questions:	 If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Ai Ping Lee (<u>AiPing.Lee@pfizer.com</u>), with the subject line "Inflammatory and Immune-Mediated Dermatologic Disorders (Global)." Please click <u>here</u> to view Frequently Asked Questions regarding the Competitive Grant Program
Review and Approval Process	 Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions. The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement
Mechanism by which Applicants will be Notified:	 All applicants will be notified via email by the dates noted above Applicants may be asked for additional clarification during the review period





Appendix A Full Proposal/Protocol

Applications will be accepted via the online portal. Full Proposal/Protocol documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal/Protocol please ensure it addresses the following:

Goals and Objectives	 Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective
Assessment of Need for the Project	 This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question
Target Audience	 Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population
	 Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods	Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan
Innovation	 Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project
Evaluation and Outcomes	 Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures
	 Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines
Anticipated Project Timeline	 Provide an anticipated timeline for your project including project start/end dates
Additional Information	If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here
	 Early-career applicants: Letter(s) of support from mentor(s) and





Inflammatory and Immune-Mediated Dermatologic Disorders (Global)

	collaborators describing how the award will advance the applicant's career.
Organization Detail	 This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project
References	Bibliography of relevant references.



